Uxin shares drop 45% as predicted by InvestingPro’s Fair Value model
Investing.com - On Thursday, Insulet Corporation (NASDAQ:PODD) reported third-quarter results that exceeded analyst expectations and raised its full-year outlook.
The tubeless insulin pump maker’s shares gained 4.11% in pre-market trading after the results.
The company posted adjusted earnings of $1.24 per share, beating the analyst consensus of $1.14. Revenue surged 29.9% YoY to $706.3 million, significantly above the $678.09 million estimate. Total Omnipod revenue, which represents the company’s core product line, jumped 31% to $699.2 million.
"We delivered strong third quarter results, a testament to our team’s exceptional performance and the transformative power of Omnipod 5 for people living with diabetes," said Ashley McEvoy, President and CEO of Insulet.
U.S. Omnipod revenue grew 25.6% to $497.1 million, while international Omnipod revenue soared 46.5% (39.9% in constant currency) to $202.1 million. The company’s gross margin improved by 290 basis points to 72.2%.
Following the strong performance, Insulet raised its full-year 2025 revenue growth guidance to 28-29% in constant currency, up from its previous outlook of 24-27%. The company also increased its gross margin guidance to above 71%, compared to its earlier projection of approximately 71%.
For the fourth quarter, Insulet expects total revenue growth of 25-28% in constant currency, with U.S. Omnipod revenue projected to increase 24-27% and international Omnipod revenue to rise 37-40%.
The company has continued expanding its product availability, recently integrating Omnipod 5 with Dexcom’s G7 Continuous Glucose Monitor in several European countries and securing reimbursement in Norway.